Christopher D. Stephen

ORCID: 0000-0002-4727-192X
Publications
Citations
Views
---
Saved
---
About
Contact & Profiles
Research Areas
  • Genetic Neurodegenerative Diseases
  • Neurological disorders and treatments
  • Botulinum Toxin and Related Neurological Disorders
  • Parkinson's Disease Mechanisms and Treatments
  • Psychosomatic Disorders and Their Treatments
  • Lysosomal Storage Disorders Research
  • Mental Health and Psychiatry
  • Metabolism and Genetic Disorders
  • Mitochondrial Function and Pathology
  • Peroxisome Proliferator-Activated Receptors
  • Neurological and metabolic disorders
  • Restless Legs Syndrome Research
  • Vestibular and auditory disorders
  • Retinoids in leukemia and cellular processes
  • Neonatal and fetal brain pathology
  • Fibromyalgia and Chronic Fatigue Syndrome Research
  • RNA regulation and disease
  • Complementary and Alternative Medicine Studies
  • Cardiovascular Function and Risk Factors
  • Nuclear Receptors and Signaling
  • Sleep and Wakefulness Research
  • Migraine and Headache Studies
  • Peripheral Neuropathies and Disorders
  • Neurological diseases and metabolism
  • Vitamin K Research Studies

Massachusetts General Hospital
2016-2025

Harvard University
2016-2025

Primary Children's Hospital
2024

Precision for Medicine (United States)
2024

American Physical Therapy Association
2022

University of Pennsylvania
2022

Massachusetts Eye and Ear Infirmary
2020-2021

Universitätsklinikum Knappschaftskrankenhaus Bochum
2020

University Hospital of Bern
2020

Ninewells Hospital
2011-2018

<h3>Importance</h3> There is limited information about health care use and costs in patients with functional neurological disorders (FNDs). <h3>Objective</h3> To assess US emergency department (ED) inpatient charges for FNDs. <h3>Design, Setting, Participants</h3> This economic evaluation used Healthcare Cost Utilization Project data to all-payer (1) adult (age, ≥18 years) hospitalizations (2008-2017), (2) pediatric 5-17 (2003, 2006, 2009, 2012, 2016), (3) ED evaluations...

10.1001/jamaneurol.2020.3753 article EN JAMA Neurology 2020-10-26

To ascertain demographic and clinical features of Parkinson disease (PD) associated with functional neurological features.A standardised form was used to extract data from electronic records 53 PD patients disorders (PD-FND) across eight movement centres in the USA, Canada Europe. These subjects were matched for age, gender duration without (PD-only). Logistic regression analysis compare both groups after adjusting clustering effect.Functional symptoms preceded or co-occurred onset 34%...

10.1136/jnnp-2017-317378 article EN Journal of Neurology Neurosurgery & Psychiatry 2018-03-16

Technologies that enable frequent, objective, and precise measurement of ataxia severity would benefit clinical trials by lowering participation barriers improving the ability to measure disease state change. We hypothesized analyzing characteristics sub-second movement profiles obtained during a reaching task be useful for objectively quantifying motor ataxia. Participants with (N=88), participants parkinsonism (N=44), healthy controls (N=34) performed computer tablet version finger-to-nose...

10.1007/s12311-021-01247-6 article EN cc-by The Cerebellum 2021-03-02

Abstract Background Objective assessments of movement impairment are needed to support clinical trials and facilitate diagnosis. The objective the current study was determine if a rapid web‐based computer mouse test (Hevelius) could detect accurately measure ataxia parkinsonism. Methods Ninety‐five ataxia, 46 parkinsonism, 29 control participants 229,017 online completed Hevelius. We trained machine‐learning models on age‐normalized Hevelius features (1) severity disease progression (2)...

10.1002/mds.27915 article EN cc-by Movement Disorders 2019-11-07

Abstract Background and purpose Despite enormous advances in identifying genetic variants responsible for many neurological diseases, access to testing may be limited clinical practice. The objective of this study was assess worldwide tests movement disorders factors impacting their utilization. Methods Rare Movement Disorders Study Group the International Parkinson Disorder Society designed an online survey electronically mailed all 7815 members. Results Survey data completed by 1269...

10.1111/ene.14826 article EN cc-by-nc-nd European Journal of Neurology 2021-03-17

Abstract X-linked dystonia parkinsonism is a neurodegenerative movement disorder that affects men whose mothers originate from the island of Panay, Philippines. Current evidence indicates most likely cause an expansion in TAF1 gene may be amenable to treatment. To prepare for clinical trials therapeutic candidates parkinsonism, we focused on identification quantitative phenotypic measures are strongly associated with disease progression. Our main objective establish comprehensive, assessment...

10.1093/braincomms/fcad106 article EN cc-by Brain Communications 2023-01-01

Abnormal eye movements occur early in the course of disease many ataxias. However, clinical assessments oculomotor function lack precision, limiting sensitivity for measuring progression and ability to detect subtle signs. Quantitative assessment during everyday behaviors such as reading has potential overcome these limitations produce functionally relevant measures. In this study, we analyze individuals with ataxia passage reading. Binocular gaze sampled at 1000 Hz was collected from 102...

10.1101/2025.01.13.25320487 preprint EN cc-by-nc-nd medRxiv (Cold Spring Harbor Laboratory) 2025-01-14

The aim of the study was to assess US inpatient and emergency department (ED) charges for functional neurologic disorder (FND), investigate subtype variations, compare costs with research funding. We used 2009-2019 Healthcare Cost Utilization Project data adult pediatric inpatient/ED stays associated in 2019 inflation-adjusted dollars, ICD-10-defined FND (F.44.4-F44.7) vs comparators neuroinflammatory/demyelinating diseases, refractory epilepsy, anterior horn cell diseases. NIH funding...

10.1212/wnl.0000000000213445 article EN Neurology 2025-02-25

ABSTRACT Background The Patient‐Reported Outcome Measure of Ataxia (PROM‐Ataxia) has been validated cross‐sectionally but not longitudinally. Objective We aimed to validate PROM‐Ataxia as a measure patient experience disease over time, examine overall and domain‐specific progression, test convergent validity with other clinical outcome assessments (COAs). Methods derived data from 176 patients spinocerebellar ataxia types 1, 2, 3, 6, 7, 8, or 10 in the Clinical Research Consortium for Study...

10.1002/mds.30158 article EN Movement Disorders 2025-03-04

Abstract Objective Frequent and objective assessment of ataxia severity is essential for tracking disease progression evaluating the effectiveness potential treatments. Wearable-based assessments have emerged as a promising solution. However, existing methods rely on inertial data features directly correlated with subjective coarse clinician-evaluated rating scales, which serve imperfect gold standards. This approach may introduce biases restrict flexibility in feature design. To address...

10.1101/2025.02.28.25323114 preprint EN cc-by medRxiv (Cold Spring Harbor Laboratory) 2025-03-04

Background and objectives Dystonia is the third most common movement disorder. Motor non-motor manifestations of dystonia may impact Health Related Quality Life (HRQoL), with lower HRQoL scores compared to healthy population. People generalized report worse (vs. people focal distributions). Social determinants health (SDOH) play a role in outcomes dystonia, but scant data exists. We aimed examine differences vs. non-focal (e.g., segmental, multifocal, generalized) association SDOH. Methods...

10.3389/dyst.2025.13711 article EN cc-by Dystonia 2025-03-12

Despite promising research and consensus recommendations on the important therapeutic role of physical therapy for motor functional neurological disorder (FND), little is known about feasibility potential efficacy implementing this population in a U.S.-based outpatient program. Given health care system differences internationally, an gap literature.In retrospective cohort study, authors investigated relationship between treatment adherence clinical outcome hospital-based Medical records 50...

10.1176/appi.neuropsych.19030068 article EN Journal of Neuropsychiatry 2019-09-30

Spinocerebellar ataxia type 35 (SCA35) is a rare autosomal-dominant neurodegenerative disease caused by mutations in the TGM6 gene, which codes for transglutaminase 6 (TG6). Mutations TG6 induce cerebellar degeneration an unknown mechanism. We identified seven patients bearing new TGM6. To gain insights into molecular basis of mutant TG6-induced neurotoxicity, we analyzed all mutants and five previously linked to SCA35. found that wild-type (TG6-WT) protein mainly localized nucleus...

10.1093/hmg/ddx259 article EN Human Molecular Genetics 2017-07-04

Eye movements are disrupted in many neurodegenerative diseases and frequent early features conditions affecting the cerebellum. Characterizing eye is important for diagnosis may be useful tracking disease progression response to therapies. Assessments limited as they require an in-person evaluation by a neurology subspecialist or specialized expensive equipment. We tested hypothesis that movement abnormalities cerebellar disorders (i.e., ataxias) could captured from iPhone video. Videos of...

10.1038/s41598-020-75661-x article EN cc-by Scientific Reports 2020-10-29
Coming Soon ...